A61K - Cooperative Patent Classification
A61K - Cooperative Patent Classification
A61K - Cooperative Patent Classification
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CPC - <strong>A61K</strong> - 2013.07 - page 81<br />
<strong>A61K</strong> 2039/515 . . Animal cells<br />
<strong>A61K</strong> 2039/5152 . . . Tumor cells<br />
<strong>A61K</strong> 2039/5154 . . . Antigen presenting cells [APCs], e.g. dendritic cells, macrophages<br />
<strong>A61K</strong> 2039/5156 . . . expressing foreign proteins<br />
<strong>A61K</strong> 2039/5158 . . . Antigen-pulsed cells e.g. T-cells<br />
<strong>A61K</strong> 2039/517 . . Plant cells<br />
<strong>A61K</strong> 2039/52 . . Bacterial cells ; Fungal cells ; Protozoal cells<br />
<strong>A61K</strong> 2039/521 . . . inactivated (killed)<br />
<strong>A61K</strong> 2039/522 . . . avirulent or attenuated<br />
<strong>A61K</strong> 2039/523 . . . expressing foreign proteins<br />
<strong>A61K</strong> 2039/525 . . Virus<br />
<strong>A61K</strong> 2039/5252 . . . inactivated (killed)<br />
<strong>A61K</strong> 2039/5254 . . . avirulent or attenuated<br />
<strong>A61K</strong> 2039/5256 . . . expressing foreign proteins<br />
<strong>A61K</strong> 2039/5258 . . . Virus-like particles<br />
<strong>A61K</strong> 2039/53 . . DNA (RNA) vaccination<br />
<strong>A61K</strong> 2039/54 . characterised by the route of administration<br />
<strong>A61K</strong> 2039/541 . . Mucosal route<br />
<strong>A61K</strong> 2039/542 . . . oral/gastrointestinal<br />
<strong>A61K</strong> 2039/543 . . . intranasal<br />
<strong>A61K</strong> 2039/544 . . . to the airways ( intranasal <strong>A61K</strong> 2039/543 )<br />
<strong>A61K</strong> 2039/545 . characterised by the dose, timing or administration schedule<br />
<strong>A61K</strong> 2039/55 . characterised by the host/recipient, e.g. newborn with maternal antibodies<br />
<strong>A61K</strong> 2039/552 . . Veterinary vaccine<br />
<strong>A61K</strong> 2039/555 . characterised by a specific combination antigen/adjuvant<br />
<strong>A61K</strong> 2039/55505 . . Inorganic adjuvants<br />
<strong>A61K</strong> 2039/55511 . . Organic adjuvants<br />
<strong>A61K</strong> 2039/55516 . . . Proteins ; Peptides<br />
<strong>A61K</strong> 2039/55522 . . . Cytokines ; Lymphokines ; Interferons<br />
<strong>A61K</strong> 2039/55527 . . . . Interleukins<br />
<strong>A61K</strong> 2039/55533 . . . . . IL-2<br />
<strong>A61K</strong> 2039/55538 . . . . . IL-12<br />
<strong>A61K</strong> 2039/55544 . . . Bacterial toxins<br />
<strong>A61K</strong> 2039/5555 . . . Muramyl dipeptides<br />
<strong>A61K</strong> 2039/55555 . . . Liposomes ; Vesicles, e.g. nanoparticles ; Spheres, e.g. nanospheres ;<br />
Polymers<br />
<strong>A61K</strong> 2039/55561 . . . CpG containing adjuvants ; Oligonucleotide containing adjuvants<br />
<strong>A61K</strong> 2039/55566 . . . Emulsions, e.g. Freund's adjuvant, MF59<br />
<strong>A61K</strong> 2039/55572 . . . Lipopolysaccharides ; Lipid A ; Monophosphoryl lipid A<br />
<strong>A61K</strong> 2039/55577 . . . Saponins ; Quil A ; QS21 ; ISCOMS
Change language